SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-005819
Filing Date
2021-03-11
Accepted
2021-03-11 16:30:51
Documents
57
Period of Report
2021-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 490295
2 ex10-1.htm EX-10.1 21012
3 ex10-2.htm EX-10.2 252823
4 ex31-1.htm EX-31.1 10898
5 ex31-2.htm EX-31.2 16242
6 ex32-1.htm EX-32.1 6721
7 ex32-2.htm EX-32.2 6653
8 ex10-2_001.jpg GRAPHIC 22421
  Complete submission text file 0001493152-21-005819.txt   3161499

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE FILE anix-20200131.xml EX-101.INS 570177
10 XBRL SCHEMA FILE anix-20200131.xsd EX-101.SCH 30149
11 XBRL CALCULATION FILE anix-20200131_cal.xml EX-101.CAL 38703
12 XBRL DEFINITION FILE anix-20200131_def.xml EX-101.DEF 121690
13 XBRL LABEL FILE anix-20200131_lab.xml EX-101.LAB 217671
14 XBRL PRESENTATION FILE anix-20200131_pre.xml EX-101.PRE 168799
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 21733719
SIC: 2834 Pharmaceutical Preparations